Nonmetastatic renal-cell carcinoma:: is it really possible to define rational guidelines for post-treatment follow-up?

被引：32

作者：

Rouvière, O

Bouvier, R

Negrier, S

Badet, L

Lyonnet, D

机构：

[1] Hop Edouard Herriot, Dept Urinary Vasc & Intervent Radiol, Lyon, France

[2] INSERM, Unit 556, Lyon, France

[3] Hop Edouard Herriot, Dept Urol Pathol, Lyon, France

[4] Hop Edouard Herriot, Leon Berard Comprehens Canc Ctr, Lyon, France

[5] Hop Edouard Herriot, Dept Urinary Vasc & Intervent Radiol, Lyon, France

来源：

NATURE CLINICAL PRACTICE ONCOLOGY | 2006年 / 3卷 / 04期

关键词：

carcinoma; nephrectomy; prognosis; renal cell; tumor markers;

D O I：

10.1038/ncponc0479

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Defining rational follow-up guidelines in patients treated for cancer is important, from both a medical and an economical perspective. Renal-cell carcinoma is reputed to be unpredictable in its course and only a few, and often contradictory, follow-up guidelines exist for patients treated for nonmetastatic renal-cell carcinoma. Recent advances in tumor biology have contributed to a better understanding of this cancer and have indicated that personalized follow-up regimens, based on tumor and host molecular characteristics, might be possible in the near future.

引用

页码：200 / 213

页数：14

共 118 条

[91] Clinical significance of cell proliferation, microvessel density, and CD44 adhesion molecule expression in renal cell carcinoma [J].